TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12356779
Drug: Isoflavone-rich soy
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone-rich soy protein diet (approximately 90 mg of total isoflavones/day)
Study: 10856150
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 100 microg twice daily (FP100BID)
Study: 10856150
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 200 microg once daily (FP200QD)
Study: 8857869
Drug: Structured depression
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured depression treatment program including behavioral treatment and counseling
Study: 8857869
Drug: Structured depression
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured depression treatment program
Study: 1535788
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oestradiol valerate for 21 days combined with 250 micrograms levonorgestrel for the last ten days
Study: 1535788
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oestradiol valerate for 21 days combined with 10 mg medroxyprogesterone acetate for the last ten days
Study: 6318543
Drug: MK-521 20
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-521 20 mg once daily
Study: 6318543
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MK-521 and Hydrochlorothiazide
Study: 31264767
Drug: Sotagliflozin 75
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Sotagliflozin 75 mg
Study: 25926620
Drug: Telcagepant 140
Normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telcagepant 140 mg
Study: 25282309
Drug: Regression analyses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regression analyses controlling for pre-treatment opioid dependence diagnosis, opioid misuse, and pain severity
Study: 12234505
Drug: Intrarectal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal lidocaine (20 cc of 2% intrarectal lidocaine 20 minutes before biopsy)
Study: 7006882
Drug: Oral ETN
Normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ETN
Study: 9847643
Drug: High-dose propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose propofol (0.3 mg/kg plus 10 mg/kg/h perfusion)
Study: 9847643
Drug: Propofol with
Normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol with nitroprusside (8 mg/kg/h perfusion)
Study: 9734496
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 3000 mg/day
Study: 1884720
Drug: Diltiazem 120-360
Normalized name: diltiazem hydrochloride 360 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 120-360 mg/day
Study: 1884720
Drug: Metoprolol 50-200
Normalized name: metoprolol tartrate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 50-200 mg/day
Study: 27040154
Drug: Carnosine 2
Normalized name: ASCORBIC ACID 200 mg / Vitamin D 20 ug / FOLIC ACID 1667 ug / CYANOCOBALAMIN 6 ug / CALCIUM CITRATE 40 mg / IRON PROTEIN SUCCINYLATE 3.6 mg / MAGNESIUM GLYCINATE 8.5 mg / MAGNESIUM OXIDE 60.3 mg / ZINC 8 mg / POLAPREZINC 37.5 mg / CARNOSINE 28 mg ORAL CAPSULE [Remedient]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnosine 2 g daily for 12 weeks
Study: 11931782
Drug: 165 microg/injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 165 microg/injection
Study: 11931782
Drug: 330 microg/injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 330 microg/injection (less intense regimen)
Study: 11931782
Drug: 330 microg/injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 330 microg/injection (more intense regimen)
Study: 11931782
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with intravitreous fomivirsen
Study: 9056060
Drug: Sucralfate (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (2000 mg twice daily for 5 days)
Study: 3527513
Drug: Brotizolam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brotizolam (0.25 mg or 0.5 mg)
Study: 25577914
Drug: Baimai ointment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baimai ointment, fomentation, functional exercises
Study: 23316290
Drug: Bromocriptine-QR (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine-QR (1.6 to 4.8 mg/day)
Study: 21189853
Drug: labetalol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol (0.25 mg/kg)
Study: 21189853
Drug: esmolol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: esmolol (0.5 mg/kg)
Study: 21189853
Drug: control (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: control (10 ml 0.9% saline)
Study: 18373383
Drug: Gepirone-ER (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepirone-ER (20 to 80 mg/day, most patients received 60 or 80 mg/day by week 3)
Study: 15747682
Drug: Single preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative dose of prophylactic antibiotic with no postoperative antibiotics
Study: 15747682
Drug: Preoperative dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative dose of antibiotics with postoperative antibiotics for 7 days
Study: 10498024
Drug: Barrier gels
Normalized name: Valiant Barrier
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Barrier gels
Study: 6203313
Drug: Verucid (comparative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verucid (comparative drug)
Study: 24988179
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid treatment (1.9 g EPA and 1.5 g DHA)
Study: 23724240
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment plus immunotherapy
Study: 23724240
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with steroids and/or tacrolimus (Control)
Study: 17369783
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy for neck pain
Study: 1663261
Drug: WC3 rotavirus
Normalized name: ROTAVIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: WC3 rotavirus vaccine
Study: 2172394
Drug: Previous rotavirus
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous rotavirus infection, high levels of WC3 neutralizing antibody, maternal serotype 1 neutralizing antibody (titer >= 30)
Study: 22587973
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment combined with comprehensive rehabilitation therapy
Study: 22587973
Drug: Comprehensive rehabilitation
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive rehabilitation therapy only
Study: 21086596
Drug: Microwave resonance
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microwave resonance therapy with 'fluctuating' frequency and varied wave range
Study: 15890591
Drug: Intrarectal amifostine
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal amifostine (1,500 mg)
Study: 15890591
Drug: Subcutaneous amifostine
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous amifostine (500 mg)
Study: 10605192
Drug: Antiretroviral agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral agents
Study: 8620521
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 300,000 IU human natural IL-2 (hnIL-2) per day for 2 weeks
Study: 8620521
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 150,000 IU human natural IL-2 (hnIL-2) per day
Study: 8620521
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 300,000 IU human natural IL-2 (hnIL-2) per day
Study: 6755208
Drug: Continue treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue treatment for 3 years
Study: 6755208
Drug: Stop treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop treatment after 18 months or 2 years
Study: 6755208
Drug: Continue treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue treatment for 2 years
Study: 29279062
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy tablets
Study: 29279062
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy drops
Study: 29279062
Drug: Both tablets
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both tablets and drops
Study: 27154364
Drug: Omega-3 fish
Normalized name: Omega-3 Fish Oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fish oil supplementation at a dose of 60mg/Kg/day
Study: 18540923
Drug: Gabapentin (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (1,500 mg or 5 pills at bedtime for 6 weeks)
Study: 14750898
Drug: Granulocyte Colony-Stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte Colony-Stimulating Factor (G-CSF) after high-dose chemotherapy with stem cell support
Study: 14750898
Drug: Granulocyte Colony-Stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte Colony-Stimulating Factor (G-CSF) in the treatment of established chemotherapy-induced febrile neutropenia
Study: 8595995
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (high dosage)
Study: 1883256
Drug: Clomipramine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (up to 300 mg/d)
Study: 17128840
Drug: Ointment base
Normalized name: Ointment base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment base
Study: 30621746
Drug: Full-dose TNF
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose TNF inhibitors (adalimumab, etanercept, infliximab, golimumab)
Study: 30621746
Drug: Reduced-dose TNF
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Reduced-dose TNF inhibitors (approximately half the standard dose)
Study: 30621746
Drug: Full-dose TNF
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose TNF inhibitors
Study: 30621746
Drug: Reduced-dose TNF
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Reduced-dose TNF inhibitors
Study: 30278544
Drug: Dezocine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dezocine 0.15 mg/kg before anesthesia induction
Study: 21517925
Drug: Mitiglinide 5
Normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mitiglinide 5 mg (fasted)
Study: 21517925
Drug: Mitiglinide 10
Normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mitiglinide 10 mg (fasted)
Study: 21517925
Drug: Mitiglinide 20
Normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mitiglinide 20 mg (fasted)
Study: 21517925
Drug: Mitiglinide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitiglinide (all doses)
Study: 21057743
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (no medical or non-medicated preparations)
Study: 17951496
Drug: 8 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g/d of Synergy (inulin-type fructans)
Study: 15699296
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER (75‐225 mg/d)
Study: 15699296
Drug: Paroxetine (20‐50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20‐50 mg/d)
Study: 12050266
Drug: Flutamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (250 mg, n = 10)
Study: 12050266
Drug: Metformin (1275
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1275 mg, n = 8)
Study: 12050266
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Flutamide + Metformin, n = 13)
Study: 10471871
Drug: Amoxicillin/clavulanate (Augmentin)
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (Augmentin) and ticarcillin/clavulanate (Timentin)
Study: 2043514
Drug: Ultrasound guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided percutaneous aspiration and lavage of the gallbladder followed by intra‐lumenal instillation of 500 mg ampicillin (PALA)
Study: 2043514
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with 500 mg of ampicillin every 6 hours for 5 days (Control)
Study: 27644162
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) treatment for a minimum of 1 month
Study: 21820829
Drug: Dose-modulated ECG-gated
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-modulated ECG-gated CT angiography
Study: 12377352
Drug: Dose-volume histograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-volume histograms (DVH) for an eccentric seed train
Study: 7926342
Drug: Multiple injections
Normalized name: sodium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple injections (4‐6 times daily)
Study: 7926342
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (twice daily)
Study: 2573264
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg daily (AT 50)
Study: 2573264
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg daily (AT 100)
Study: 2573264
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg twice a day (Prop)
Study: 28228317
Drug: SAXA-MET (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAXA-MET (5 mg/2,000 mg)
Study: 28228317
Drug: MET (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET (2,000 mg)
Study: 28228317
Drug: SAXA (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAXA (5 mg)
Study: 22108474
Drug: Silver Oxide
Normalized name: Silver Oxide
DrugBank: Silver oxide (DB15668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver Oxide Ointment
Study: 19370045
Drug: 16.6 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16.6 g of whey protein + 3.4 g of leucine (W+L)
Study: 15378556
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg divalproex sodium extended-release (divalproex-ER)
Study: 15378556
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg divalproex sodium extended-release (divalproex-ER)
Study: 11387490
Drug: Ultrasound contrast
Normalized name: ULTRASOUND CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound contrast agent (Levovist, 300 mg/mL, 1 mL/min)
Study: 11387490
Drug: No ultrasound
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ultrasound contrast agent (USCA)
Study: 11387490
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of USCA
Study: 9409267
Drug: Endothelin-1 (ET-1)
Normalized name: nitric oxide synthase endothelial
DrugBank: Endothelin-1 (DB12652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin-1 (ET-1) administered intravenously for 6 hours
Study: 9409267
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously for 6 hours
Study: 8494374
Drug: Intensive aluminum‐magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive aluminum‐magnesium hydroxide antacid regimen (Maalox TC) administered at multiple time points relative to enoxacin infusion.
Study: 8494374
Drug: Intravenous enoxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous enoxacin (400 mg) administered without antacid treatment.
Study: 3317784
Drug: Budesonide enema,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide enema, 2 mg/100 ml
Study: 3317784
Drug: Prednisolone disodium
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone disodium phosphate enema, 31.25 mg/100 ml
Study: 28211882
Drug: Aflibercept (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept (2 mg) administered as three monthly intravitreal injections followed by two bi-monthly injections and a final examination at week 28.
Study: 21464563
Drug: Ultrasound-assisted wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-assisted wound treatment (UAW)
Study: 18493214
Drug: Long-chain polyunsaturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-chain polyunsaturated fatty acids (LCPUFAs) supplementation (AA: 20-30 mg daily, DHA: 14-21 mg daily)
Study: 16566900
Drug: Fludrocortisone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone (0.5 mg)
Study: 9089582
Drug: liposome-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: liposome-adjuvanted vaccine
Study: 9089582
Drug: control subvirion
Approvals — FDA: no, EMA: no, PMDA: no
Description: control subvirion vaccine
Study: 1337623
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg lomefloxacin once daily for 3 days (L3)
Study: 1337623
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg lomefloxacin once daily for 7 days (L7)
Study: 1337623
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg norfloxacin twice daily for 7 days (N7)
Study: 31479209
Drug: Standard-treatment group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-treatment group (ticagrelor or prasugrel)
Study: 27465112
Drug: Education plus
Normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education plus decolonization without reminders (intranasal mupirocin ointment twice daily for 7 days and chlorhexidine gluconate on the first and last day)
Study: 27465112
Drug: Education plus
Normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education plus decolonization with reminders (daily telephone call or text message reminders)
Study: 17043094
Drug: Arm B
Normalized name: arm brace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B (weekly): gemcitabine 1000 mg/m2 and paclitaxel 100 mg/m2 on days 1 and 8 of a 21-day cycle
Study: 17043094
Drug: Arm A
Normalized name: Warm antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A (three-weekly): gemcitabine 1000 mg/m2 on days 1 and 8 and paclitaxel 200 mg/m2 on day 1 of a 21-day cycle
Study: 16253098
Drug: SRP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP and 400 mg systemically administered metronidazole (MET) three times per day for 10 days
Study: 10640634
Drug: Reciprocally organized
Normalized name: Organic germanium
DrugBank: Propagermanium (DB17608)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reciprocally organized agonist and antagonist muscle activity
Study: 27269279
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (0.2 mg/ml)
Study: 31472446
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg po bid
Study: 30325687
Drug: HTP (hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTP (hyaluronic acid-based topical lubricant)
Study: 22975536
Drug: Methimazole +
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole + β‐blockers
Study: 22975536
Drug: Methimazole without
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole without β‐blockers
Study: 15857284
Drug: Brinzolamide 1%
Normalized name: BRINZOLAMIDE 1% SUSP,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brinzolamide 1% (twice a day)
Study: 26483224
Drug: Montelukast (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (4 mg once a day for 7 days)
Study: 26483224
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine medical treatment only)
Study: 23596782
Drug: Shugan Jianpi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shugan Jianpi Gusui Recipe (SJGR) administered during the remission phase
Study: 23596782
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with azathioprine alone or no treatment
Study: 21331063
Drug: Insulin Resistant
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin Resistant (IR) group